Shots:
- Aqua Medical has received the US FDA IDE approval to initiate the RESTORE-1 study evaluating the Proximal Intestinal Mucosal Ablation (PIMA) procedure using its radiofrequency vapor ablation (RFVA) system in adults with uncontrolled type 2 diabetes
- The IDE approval was backed by international data showing safety & metabolic benefits of PIMA, allowing Aqua Medical to prepare for US site activation & patient enrollment
- PIMA is a minimally invasive, outpatient endoscopic procedure that uses a through-the-endoscope RFVA catheter to ablate 50–70 cm of the proximal intestine, aiming to replicate gastric bypass metabolic benefits without surgery or fluoroscopy
Ref: PRNewsWire | Image: Aqua Medical | Press Release
Related News:- Pulse Biosciences Receives FDA IDE Approval for nsPFA Cardiac Surgery System to Treat Atrial Fibrillation
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
